Immunotherapy plus chemo and radiation: new hope for lung cancer?
NCT ID NCT07138755
First seen Apr 10, 2026 · Last updated Jun 21, 2026 · Updated 10 times
Summary
This phase 2 trial tests whether adding the immunotherapy drug sintilimab to standard chemotherapy and a tailored radiation plan can help people with stage III non-small cell lung cancer. The study will enroll 35 adults who cannot have surgery. Researchers will track how long the cancer stays under control and any side effects.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NSCLC are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Xiangya 3rd Hospital, Central South University
RECRUITINGChangsha, Hunan, 410013, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Sintilimab (an immunotherapy drug) combined with platinum-based chemotherapy (cisplatin or carboplatin plus paclitaxel or pemetrexed) and adaptive radiotherapy
What this could lead to
If successful, this combination could improve control of stage III lung cancer and delay disease progression, offering a new treatment option.
What could go wrong
This is a small, early-phase trial with only 35 participants, so results may not apply broadly. Side effects from the drug combination and radiation are possible.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.